ENDPOINTS

#AAN25: J&J, argenx keep rolling out myasthenia gravis ...

Last weekend, researchers gathered in San Diego for the American Academy of Neur...

Alzheon’s amyloid-targeting pill fails another Alzheime...

Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could of...

Biotech CEOs to Cassidy: We're already seeing the effec...

Biopharma companies with pending applications at the FDA have "already encounter...

Study: Therapy AI chatbot shows promising results

A trial of an AI chatbot built for mental health treatment has shown that it can...

Exclusive: Cardiometabolic biotech gets $57.5M Series B...

A biotech incubated by RA Capital has secured a $57.5 million Series B to begin ...

Firings of HHS' probationary workers can proceed, appea...

HHS and 19 other government agencies can follow through with firing thousands of...

ICER outlines ways to increase GLP-1 access as costs rise

The nonprofit drug pricing watchdog, the Institute for Clinical and Economic Rev...

Biotech market meltdown will leave some startups lookin...

It’s a biotech environment without many good choices. Even before President ...

Idorsia’s blood pressure pill no longer requires a REMS...

Plus, news about Vincerx and Cytora: Idorsia’s Tryvio gets safety restrictio...

Novo Nordisk looks to Brazil to boost GLP-1 manufacturi...

Novo Nordisk is pouring 6.4 billion Brazilian reais ($1.05 billion) into a facto...

Pharma is next in line as Trump says tariffs are coming...

President Donald Trump warned on Tuesday evening that “major” pharmaceutical tar...

Pharma CEOs warn EU of potential US exodus as trade war...

Executives of major pharmaceutical companies warned the European Union that they...

House panel mulls ways to boost struggling biosimilar m...

The state of the US biosimilar market isn't as healthy as it should be despite s...

NIH appeals nationwide block on indirect cost cuts

The Trump administration on Tuesday said it will challenge a federal judge’s ord...

What stock market chaos means for health tech

The markets have been volatile over the past few days, turned upside down by the...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.